Scott Moffitt, Managing Director of BioNova, the host of BIC, announced the semi-finalists, which included Tieos Pharmaceuticals. All semi-finalists will receive professional pitch training between now and the semi-final run off, which will be held in Halifax on October 17.

VANCOUVER, BC, August 17, 2017. Reliq Health Technologies Inc. a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community‐Based Healthcare, is pleased to announce the golive of remote patient monitoring, care coordination and telemedicine platform with their Rio Grande Valley Health Alliance in McAllen, Texas.

TORONTO and CAMBRIDGE, Mass., Aug. 17, 2017. BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announces the expansion of the company's presence in Toronto with a research, development and manufacturing site in the MaRS Discovery District.

The Consulate General of Canada in Boston and MassMEDIC invite emerging Canadian medtech companies to apply to participate in Canadian Mission to MassMEDIC’s MedTech Showcase, on October 26-27, 2017.

Sernova Corp, a leading clinical stage regenerative medicine company, announced that FronTier Merchant Capital Group will provide North American investor relations (IR) and strategic marketing for Sernova with a goal of increasing market awareness through financial market communications.

A new study conducted bythe Canadian Concussion Centre and Dr. Charles Tator has shown that Iris Technologies' Non-LCD E-Paper Technology can decrease the risk of exacerbating symptoms in sufferers of post-concussion syndrome (PCS).

US FDA unveiled its Digital Health Innovation Action Plan last week, including a Software Pre-Certification Pilot Program to facilitate faster market access for digital health products.

BIO Investor Forum, an international biotech investor conference focused on early and established private companies, is now accepting applications to present at the October 17-18, 2017 event in San Francisco.

In partnership with Global Affairs Canada, Ontario's Ministry of International Trade is organizing a Health Trade Mission to Japan and Korea, targeting business opportunities in these two important markets.

Jumpstarter is a first-of-its-kind startup event that unites and empowers Hong Kong’s hottest startup sectors.

OBIO member company Steadiwear Inc. took home the titles of "Most Innovative Start-up” in the Wearables/IOT/EduTech  Pitch Competition, and the “Most Favorable Startup”, as decided by audience votes, which earned them a spot in the Grand Finale.

Intronix Technologies will be launching "Myoguide DOC", a comprehensive software package designed to help clinicians who inject Botulinum Toxins, such as Botox®, Dysport® and Xeomin® to manage their patient's spasticity and pain.

Mirexus Biotechnologies Inc. (Mirexus) is excited to announce that it has closed an investment round of $12 million.  Mirexus is a safe and natural nanomaterials company based in Guelph, Ontario that is commercializing PhytoSpherixTM, a novel technology based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to applications in human health.  The funds will be used to finance a factory to produce PhytoSpherixTM, and to fund at least three years of operations as the company grows.

Norgen Biotek Corp., an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein purification and stabilization, today announced the recent launch of their new portfolio of product and service solutions for Next Generation Sequencing (NGS) applications.  Norgen has extensive experience with NGS, and has leveraged this expertise to develop a number of new kits and workflows for NGS applications.

Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz has been appointed to the company’s Clinical Advisory Board (CAB).

A newly published study provides further data showing Straticyte offers better predictive insight over histopathological dysplasia grading for oral potentially malignant lesion assessment.